Short-term diabetes decreases ischemia reperfusion-induced arrhythmia: the effect of alpha-2 blocker yohimbine and glibenclamide

Abstract

This study examined the effect of yohimbine alone and in combination with glibenclamide on ischemia and reperfusioninduced arrhythmias in diabetes. Six minutes of ischemia were produced in 1-week diabetic rats by ligation of the left coronary artery, and 6 min of reperfusion were produced by releasing the artery. A dose of 5 mg/kg of yohimbine and glibenclamide was administered for 7 days prior to the coronary ligation. The blood pressure, heart rate, and arrhythmia were determined from the recorded ECG during the 6 min of ischemia and reperfusion and then compared using a one-way ANOVA statistical program and the chi-square test. The score of arrhythmia calculated from the type and duration of arrhythmia decreased in the diabetic rats (3.5 ± 1.69 in control, 1.7 ± 0.81 in diabetes group). The arrhythmia score returned to the control value in the rats that were given a combination of yohimbine and glibenclamide (3 ± 1.73). Yohimbine is used in the treatment of erectile dysfunction; glibenclamide is used as an antidiabetic drug in diabetic patients and may be a risk factor in the increase of ischemia reperfusion-induced arrhythmias.

The effect of acute or long-term genistein administration on the ischemia/reperfusion-induced arrhythmia in rats

“…Descending branch of left coronary artery (LAD) was ligated by tightening the silk thread by forming a bowknot to produce myocardial ischemia for 6 minutes and reperfusion was made by loosening the thread for 6 minutes. 11 At the end of the coronary ligation and reperfusion, the heart was perfused by the way of the aorta by giving firstly sodium chloride (NaCI) and then ethanol to determine the risk of infarct zone. Then the non-perfused area that seen red in color was separated from the perfused area that is seen white in color.…”